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Abstract
Background:  In contrast to most other forms of cancer, data from some developing and
developed countries show surprisingly similar survival rates for ovarian cancer. We aimed to
compare ovarian cancer survival in Philippine residents, Filipino-Americans and Caucasians living in
the US, using a high resolution approach, taking potential differences in prognostic factors into
account.
Methods: Using databases from the SEER 13 and from the Manila and Rizal Cancer Registries, age-
adjusted five-year absolute and relative survival estimates were computed using the period analysis
method and compared between Filipino-American ovarian cancer patients with cancer patients
from the Philippines and Caucasians in the US. Cox proportional hazards modelling was used to
determine factors affecting survival differences.
Results: Despite more favorable distribution of age and cancer morphology and similar stage
distribution, 5-year absolute and relative survival were lower in Philippine residents (Absolute
survival, AS, 44%, Standard Error, SE, 2.9 and Relative survival, RS, 49.7%, SE, 3.7) than in Filipino-
Americans (AS, 51.3%, SE, 3.1 and RS, 54.1%, SE, 3.4). After adjustment for these and additional
covariates, strong excess risk of death for Philippine residents was found (Relative Risk, RR, 2.45,
95% confidence interval, 95% CI, 1.99-3.01). In contrast, no significant differences were found
between Filipino-Americans and Caucasians living in the US.
Conclusion: Multivariate analyses disclosed strong survival disadvantages of Philippine residents
compared to Filipino-American patients, for which differences in access to health care might have
played an important role. Survival is no worse among Filipino-Americans than among Caucasians
living in the US.
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Background
Ovarian cancer is the second most common gynaecologi-
cal cancer worldwide and the sixth most common cancer
in women overall [1,2]. The majority of cancer cases occur
in developed countries, and age standardized incidence
and mortality rates are about two-fold higher in more
affluent nations (10.2 and 5.7 per 100,000 population) as
compared to less developed nations (5 and 2.9 per
100,000) [2]. However, there is large variation within
both groups of countries. Within countries, ovarian cancer
incidence and mortality have likewise been reported to
vary between racial groups. The incidence rate of Philip-
pine residents in 2002 was estimated at 11.5 per 100,000
[3] as compared to 10.3 for Caucasians and 8.9 for Asian
and Pacific Islanders (API) in the United States [4]. Mor-
tality rates were reported as 6.3 [3], 6 and 3.3 [4] per
100,000 for Philippine residents, Caucasians and APIs,
respectively.
Comparisons in ovarian cancer survival between devel-
oped and developing nations, as well as between ethnic
groups within countries, are few [5-7], but are important
in determining sources of population survival discrepan-
cies. In contrast to most other cancers, limited data from
some developed and developing countries suggest that
five-year relative survival rates were surprisingly similar,
ranging from 31 to 42% and from 16 to 51%, respectively
[2]. In the US, non-Hispanic white women were reported
to have reduced risk of death as compared to African-
Americans but have an increased risk compared to Fili-
pino-American women [5]. However, previous compara-
tive studies between developing and developed countries
did not take into account potential differences in major
prognostic factors, such as stage at diagnosis or morphol-
ogy, which have been reported to vary between ethnic
groups [5].
In this paper, we take a "high resolution" approach [8-10]
to elucidate the role of factors not routinely available in
population-based cancer registries, including ethnicity,
stage at diagnosis, morphology, and access to treatment,
in comparing ovarian cancer survival between Philippine
resident patients, Filipino-Americans and Caucasians liv-
ing in the US.
Methods
Databases
United States SEER 13
Using the Surveillance, Epidemiology and End Results
(SEER) 13 database [4], ovarian cancer patients of Fili-
pino-American or of Caucasian origin, including those of
Hispanic ethnicity, were identified. Patients aged 15 and
older, diagnosed with malignant ovarian cancer between
January 1, 1993 and December 31, 2002 and followed
with respect to vital status until December 31, 2002 were
included in the study.
Manila and Rizal Cancer Registries
Patient information for residents of the National Capital
Region (NCR) of the Philippines was abstracted from the
Philippine Cancer Society-Manila Cancer Registry (PCS-
MCR) and the Department of Health-Rizal Cancer Regis-
try (DOH-RCR). The registries are regarded as among the
high-quality registries from developing countries and
have consistently been included in the "Cancer Incidence
in Five Continents" series [11-15]. They follow cancer reg-
istration definitions and data collection guidelines set by
the International Agency for Research on Cancer (IARC)
and the International Association of Cancer Registries
(IACR) [16].
Using the same inclusion and exclusion criteria as for the
SEER databases, a list of 2,898 ovarian cancer cases diag-
nosed between 1998 and 2002 was generated, from which
sub samples of 200 cases diagnosed in each calendar year
of interest were randomly drawn using the .sample com-
mand in STATA version 6 [17]. Patients were followed
with respect to vital status until December 31, 2002 as fol-
lows: survival status was assessed from death certificate
notifications mentioning cancer as the cause of death,
which were collected from Local Civil Registry Offices. For
those not identified as dead, active follow-up by personal
visits to the patients' last known place of residence were
done to confirm vital status.
The project proposal was approved by the Ethics Review
Board of the National Institutes of Health of the Univer-
sity of the Philippines Manila. The information obtained
strictly conformed to the code of conduct stipulated by the
Guidelines on Confidentiality for Population-based Can-
cer Registries [16].
Data analysis
Estimation of Survival using Period Analysis
To derive survival estimates, cohort-based analyses such
as the conventional life-table (actuarial) method or the
Kaplan-Meier method [18,19] have traditionally been
used. With the cancer database including cancer incidence
and follow-up data from 1993 to 2002, a cohort based
analysis would typically have pertained to patients diag-
nosed in 1993-1997 and followed through 2002 (see fig-
ure 1, framed area). To derive more up-to-date survival
estimates, we employed period analysis, a new method of
survival analysis introduced by Brenner and Gefeller in
1996 [20]. Here, only the survival experience of patients
for the 1998-2002 period was included (see figure 1,
shaded area). This was done by left truncation of observa-
tions at the beginning of the period and right censoring at
its end (i.e. at December 31, 2002 or the last date knownBMC Cancer 2009, 9:340 http://www.biomedcentral.com/1471-2407/9/340
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alive). It has been consistently shown by multiple empir-
ical evaluations that period analysis provides more up-to-
date estimates of survival expectations for patients diag-
nosed in the respective period [21-25].
Estimation of Relative Survival
As commonly practiced in population-based cancer sur-
vival analysis, both absolute and relative survival rates
were calculated. The relative survival probabilities are esti-
mated as ratios of the observed survival of cancer patients
and the expected survival of a group of people with the
same age and sex distribution from the general popula-
tion, and reflect the survival experience of cancer patients
in the absence of competing causes of death [26,27].
Using the so-called Ederer II method [28], expected sur-
vival was derived from life tables for the year 2000. For the
SEER populations, the life table for whites from the US
National Center for Health Statistics [29] were used. The
life table for the Philippine resident population was
derived from the projected population estimate and the
actual mortality data for this area, which were obtained
from the Philippine National Statistics Office.
Age adjustment
To enable comparison of ovarian cancer survival estimates
between different cancer populations, age adjustment was
done. Age-specific period survival estimates (absolute and
relative), using age groups 15-39, 40-49, 50-59, 60-69 and
70 and above, were first obtained from the Philippine res-
ident, the Filipino-American and the Caucasian popula-
tions. The age-specific estimates were then weighted and
summed for each population group, using weights from
the World Standard Cancer Patient Population (WSCPP)
[30].
Tests for survival differences between cancer patient populations
The differences between survival estimates for the three
cancer patient populations were tested for statistical sig-
nificance using a novel modelling approach for period
analysis [31]. First, age-specific numbers of patients at risk
and of deaths by year of follow-up were calculated for
each population group. Poisson regression models were
then fitted, wherein the numbers of deaths were modelled
as a function of the population group (entered as a cate-
gorical variable), year of follow-up (1, 2, 3, 4, 5 - entered
as a categorical variable) and age-group (as described
above - entered as a categorical variable), using the loga-
rithm of the person-years at risk as offset, and accounting
for late entries and withdrawals as half persons, as
described in detail elsewhere. This allowed for testing of
significance of differences in survival, after adjustment for
age and based on p-values for the population parameter
estimate. A significance level of alpha = 0.05 (two-sided
testing) was used.
Multivariate analysis
To explain possible survival differences and identify fac-
tors affecting survival, both within and between the three
Principle of period analysis Figure 1
Principle of period analysis. Database used to derive the cohort analysis estimates (solid frame) and period analysis esti-
mates (shaded area). The numbers within the cells indicate the years of diagnosis
1 2002
1/2 1 2001
2/3 1/2 1 2000
3/4 2/3 1/2 1 1999
4/5 3/4 2/3 1/2 1 1998
5 4/5 3/4 2/3 1/2 1 1997
5 4/5 3/4 2/3 1/2 1 1996
5 4/5 3/4 2/3 1/2 1 1995
5 4/5 3/4 2/3 1/2 1 1994
5 4/5 3/4 2/3 1/2 1 1993
2002 2001 2000 1999 1998 1997 1996 1995 1994 1993
Year of follow-up Year of 
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cancer patient populations, the Cox Proportional Hazards
model was used. For each population group, bivariate
associations of age, stage at diagnosis, histology, and
receipt of surgery and of radiotherapy with survival were
determined using individual Cox models. A multivariate
model was then built jointly for all three groups to com-
pare survival probabilities between populations. Relative
hazards were calculated using Filipino-Americans as the
reference group, while controlling for the effects of age,
stage, histology, surgery and radiotherapy, first individu-
ally and then simultaneously. Those with missing infor-
mation were excluded in the multivariate analysis. The
assumption of proportional hazards for Cox models was
checked by plotting the log of the negative log of the sur-
vival density functions vs the log of survival time. The
plotted lines were roughly parallel over time and no vio-
lations of the proportional hazards assumption were
found.
Age at diagnosis was categorized into the age adjustment
groupings mentioned earlier. Stage categories were based
on the Federation of Gynecology and Obstetrics (FIGO)
stages I, II III and IV [32]. Histology was classified based
on the International Classification of Diseases for Oncol-
ogy (ICD-O) and the Systematized Nomenclature of Med-
icine [33] (serous, clear cell, endometrioid, mucinous and
other types, including Brenner, granulosa cell, germ cell
and sex cord stromal cell tumors). For the receipt of surgi-
cal treatment and of radiotherapy, binary variables (with/
without) were used. A sub-analysis for the receipt of
chemotherapy was done for all the Philippine residents
included in the study, but chemotherapy and hormone
therapy were not included in the Cox models as these
were not available from the SEER public use database.
All analyses were done with the SAS Statistical Analysis
Software. Special macros were used for standard and mod-
elled period survival analysis as previously described
[31,34].
Results
A total of 463 Filipino-American and 22,290 Caucasian
ovarian cancer patients were included in the analysis, after
exclusion of around 1% of cases who are coded in situ and
those who were identified by death certificates only
(DCO). From the 2,000 randomly sampled patients from
the Philippine databases, 1,475 ovarian cancer patients
(73.8%) were included after 220 (11%) and 305 (15.2%)
patients were removed due to invalid data, such as incor-
rect age, sex and primary site, and due to the absence of
any survival time information, respectively. Of the
included patients not known to be dead, complete 5-year
follow-up information was obtained for 33.8%, while at
least some follow-up could be ascertained for another
41.3%.
The distribution of cases by age groups, stage at diagnosis,
histology, surgery and radiotherapy are shown for each
population in Table 1. Caucasian patients were older than
other groups, with more than 50% aged 60 or above while
Philippine residents were youngest with more than 50%
below 50 years. Around half of patients were diagnosed in
the advanced stages (stages III and IV) in the Philippine
resident population and Filipino-Americans, while the
majority (66%) of Caucasians presented with advanced
stage disease. Histologic profile varied, with Caucasians
having the highest proportion of serous cancers (42%)
and fewest proportions of endometrioid (14%) and muci-
nous (7%) types. Filipinos from the Philippines have the
highest proportions of endometrioid (22%) and muci-
nous (24%) types with the smallest proportion of serous
cancers (20%). Between 78 and 90% of patients under-
went surgery and less than 10% received radiotherapy in
all groups. Of the Philippine resident patients with known
chemotherapy status, 24% received this treatment.
Age adjusted and age-specific estimates of absolute and
relative 5-year survival are shown in table 2. Five-year over
all relative survival was within a narrow range (49.3-
54.1%) in the three cancer patient populations. With few
exceptions (which, given the relatively large standard
errors in some of the age specific survival estimates, might
be due to chance variation) relative survival decreased
with age in all three cancer patient populations. Strong,
statistically significant disadvantages in 5-year absolute
and relative survival were seen in patients from the Philip-
pines compared to Filipino-American patients in age
groups 50-59 and 60-69.
As shown in table 3, late stage at diagnosis and not receiv-
ing surgery were all strongly related to the risk of dying in
each of the three populations. Furthermore, compared to
patients with serous cancers, prognosis tended to be sub-
stantially better in patients with endometrioid, clear cell
and mucinous cancer, and less favorable in patients with
other forms of cancer. A sub-analysis among the Philip-
pine residents showed that not receiving chemotherapy
was also related to the risk of death (RR, 1.54; 95% CI
1.22-1.94).
In bivariate comparative survival analysis between popu-
lation groups (table 4), substantial excess risk of death
was seen among ovarian cancer patients from the Philip-
pines and Caucasians as compared to Filipino-American
patients. For Philippine residents, excess mortality was
further increased when controlling for age and stage at
diagnosis, and quite substantial excess mortality was
found (RR, 2.45; 95% CI, 1.99-3.01) after controlling for
these and other factors in multivariate analysis. The excess
risk of Caucasian ovarian cancer patients compared to Fil-
ipino-American ovarian cancer patients was mostlyBMC Cancer 2009, 9:340 http://www.biomedcentral.com/1471-2407/9/340
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explained by the age and stage differences, and no signifi-
cant difference persisted in the multivariate analysis (RR,
1.17, 95% CI, 0.99-1.37).
Discussion
In this "high resolution" study comparing ovarian cancer
survival in the Philippine resident and Filipino-American
patients, sharing the same ethnicity, and in Filipino-
American and Caucasian patients in the US, sharing the
same health care system, overall survival differences were
found to be relatively small. However, Philippine resident
patients showed a more favorable distribution with
respect to major prognostic factors, such as age, stage and
morphology, and major excess mortality in this patient
group was disclosed after control for these factors in age
specific and multivariate analysis. By contrast, an appar-
ent survival disadvantage of Caucasian patients compared
to Filipino-American patients essentially disappeared
after controlling for these factors. Taken together, these
results point to the relevance of health care related factors
for explaining survival differences.
Disadvantages in absolute and relative survival of Philip-
pine residents compared to Filipino-Americans were par-
ticularly large for age groups 50-59 and 60-69, which can
be explained to some extent by more unfavorable stage
distributions. The proportions of patients presenting with
advanced stages in age groups 50-59 and 60-69 were
much lower in Filipino-Americans (48.4 and 55%, respec-
tively) than among Philippine residents (60.4 and 69.2%,
respectively).
Table 1: Tumor characteristics of ovarian cancer patients, Philippine resident population, and Filipino-Americans and Caucasians from 
US SEER, 1993-2002
Philippine resident population Filipino-Americans Caucasians
Variable (N = 1475) (N = 463) (N = 22290) p-value
Freq %1 Freq %1 Freq %1
Age group
< 40 415 28.1 64 13.8 1545 6.9 < 0.0001
40-49 364 24.7 110 23.8 2948 13.2
50-59 355 24.1 130 28.1 4356 19.5
60-69 213 14.4 81 17.5 4787 21.5
70+ 128 8.7 78 16.9 8654 38.8
FIGO
I 316 33.5 160 35.9 4989 24.0 < 0.0001
II 112 11.9 62 13.9 2013 9.7
III 315 33.4 138 30.9 8222 39.5
IV 201 21.3 86 19.3 5609 26.9
Unknown 531 17 1457
Morphology
Serous 236 20.1 130 30.2 8520 42.4 < 0.0001
Clear cell 72 6.1 44 10.2 974 4.9
Endometrioid 259 22.1 83 19.3 2897 14.4
Mucinous 285 24.3 45 10.5 1453 7.2
Others 320 27.3 128 29.8 6255 31.1
NOS2 303 33 2191
Surgery
With surgery 1214 88.6 396 85.7 17490 78.7 < 0.0001
Without surgery 157 11.5 66 14.3 4743 21.3
Unknown 104 1 57
Radiotherapy
With radiotherapy 95 7.7 12 2.6 437 2.0 < 0.0001
Without radiotherapy 1144 92.3 445 97.4 21732 98.0
Unknown 236 6 121
1percentages refer to those with known categories
2includes: Neoplasms; Carcinoma, NOS; Carcinoma, Undifferentiated, NOSBMC Cancer 2009, 9:340 http://www.biomedcentral.com/1471-2407/9/340
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In the absence of effective screening methods, only a small
proportion of ovarian cancer cases are diagnosed in early
stages, where surgery alone will be effective [32,35,36].
Most cases were diagnosed as advanced disease, where
chemotherapy is administered either as neo-adjuvant or
adjuvant treatment [32,35,36]. The proportion of those
given chemotherapy among Philippines residents is much
lower than an estimated 65% for US patients [32], which
is likely to be reflective of both the larger proportion of
cases in later stages in US patients, and the poor access to
chemotherapy among Philippine residents.
In developed countries, survival rates have improved in
the recent decades [37-40], mainly due to progress in
treatment, including the development of adequate
debulking surgical procedures and effective chemother-
apy regimens. Even with advanced stage, patients with no
gross residual after the surgical debulking have a consider-
ably better prognosis than those with minimal or exten-
sive residual. The number of residual sites also appears to
be important [41]. Current chemotherapy protocols are
based on the experience of developed countries and its
effectiveness do not necessarily translate in developing
country settings, given the differences in resources and
attitudes [42]. The availability and affordability of drugs
differ between the developed and developing world, and
complex chemotherapy regimens might not be feasible or
affordable in low income nations [42]. Furthermore,
patients might not complete prescribed regimens due to
financial constraints [42], as most chemotherapy drugs
are paid for privately in developing countries [43].
In the NCR, Philippines, adjuvant chemotherapy has been
shown to improve survival [44]. However, while chemo-
therapy is available and at par with the western world, the
distribution of specialized centers offering cancer care
services is not proportionate, with most located in the
major cities [45]. Moreover, most state of the art diagnos-
tic and treatment facilities are situated in tertiary private
hospitals, which typically are expensive and beyond the
means of average citizens. While subsidized services are
provided by government institutes, these are limited and
represent only a fraction of the total number of hospitals.
Compounding the problem among Philippine residents
is the persistent disbelief in chances to be cured from can-
cer [46]. In spite of health information campaigns, many
in the country still perceive cancer as a highly fatal disease
that leads to eventual death. When faced with high costs,
difficult and long treatment process, and low or unsure
chances of survival, many patients opt to either refuse or
Table 2: Five-year absolute and relative survival (in %) of ovarian cancer patients adjusted to the World Standard Cancer Patient 
Population, Philippine resident population, and Filipino-Americans and Whites from US SEER, 1998-2002
Variable (1) Philippine resident 
population
Between (1) and (2) (2) Filipino-Americans Between (3) and (2) (3) Caucasians
% SE Diff p-value % SE Diff p-value % SE
Absolute 
Survival
Over all 
survival
44.0 2.9 7.4 0.02 51.3 3.1 -4.6 0.29 46.7 0.5
Age group
< 40 64.1 4.6 11.6 0.27 75.7 7.5 0.8 0.67 76.5 1.6
40-49 55.8 4.9 -1.1 0.99 54.8 6.7 7.9 0.11 62.6 1.3
50-59 38.2 4.8 25.8 < 0.001 64.0 5.9 -12.8 0.04 51.2 1.1
60-69 36.1 6.3 17.2 0.02 53.3 8.5 -13.4 0.13 40.0 1.0
70+ 34.6 8.0 -12.7 0.03 21.9 6.0 -2.6 0.86 19.3 0.6
Relative 
Survival
Over all 
survival
49.7 3.7 4.5 0.01 54.1 3.4 -4.8 0.33 49.3 0.5
Age group
< 40 64.6 4.6 11.5 0.30 76.0 7.6 0.8 0.67 76.9 1.6
40-49 57.0 5.1 -1.6 0.99 55.4 6.8 8.0 0.11 63.4 1.3
50-59 40.0 5.0 25.8 < 0.001 65.8 6.1 -13.1 0.05 52.7 1.1
60-69 40.4 7.1 16.7 0.05 57.0 9.1 -14.1 0.14 43.0 1.1
70+ 50.8 11.7 -23.0 0.03 27.8 7.6 -2.6 0.74 25.2 0.8
Diff, difference; SE, standard errorBMC Cancer 2009, 9:340 http://www.biomedcentral.com/1471-2407/9/340
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Table 3: Relative risk of death according to various prognostic factors among ovarian cancer patients, Philippine resident population 
and from Filipino-Americans and Caucasians from US SEER, 1993-2002, Bivariate analysis
Variable Philippine resident population Filipino-Americans Caucasians
RR 95% CI RR 95% CI RR 95% CI
Age group
< 40 1.00 1.00 1.00
40-49 1.26 0.94 - 1.68 1.82 1.01 - 3.28 1.78 1.57 - 2.02
50-59 1.80 1.37 - 2.36 1.31 0.72 - 2.36 2.50 2.22 - 2.81
60-69 2.06 1.52 - 2.78 1.84 0.98 - 3.44 3.54 3.15 - 3.97
70+ 2.67 1.91 - 3.73 4.08 2.29 - 7.28 6.94 6.20 - 7.76
FIGO Stage
I 1.00 1.00 1.00
II 2.37 1.42 - 3.97 2.28 1.20 - 4.34 2.75 2.50 - 3.02
III 7.06 4.78 - 10.43 5.23 3.19 - 8.57 5.18 4.82 - 5.56
IV 14.28 9.59 - 21.26 12.54 7.60 - 20.70 9.08 8.45 - 9.75
Morphology
Serous 1.00 1.00 1.00
Endometrioid 0.80 0.48 - 1.31 0.51 0.27 - 0.98 0.61 0.54 - 0.68
Clear cell 0.85 0.61 - 1.18 0.50 0.30 - 0.83 0.51 0.48 - 0.55
Mucinous 0.67 0.47 - 0.95 0.46 0.23 - 0.90 0.61 0.56 - 0.67
Others 1.55 1.16 - 2.07 1.14 0.79 - 1.65 1.55 1.49 - 1.62
Surgery
With surgery 1.00 1.00 1.00
Without surgery 3.10 2.44 - 3.94 6.30 4.50 - 8.82 5.18 4.97 - 5.39
Radiotherapy
With radiotherapy 1.00 1.00 1.00
Without radiotherapy 1.25 0.87 - 1.79 1.20 0.44 - 3.26 1.25 1.09 - 1.43
RR, Relative Risk; 95% CI, 95% Confidence interval
Table 4: Relative risk of death for ovarian cancer patients from the Philippine resident population and for Caucasian patients 
compared to Filipino-American patients from US SEER, 1993-2002
Variable Philippine resident population Filipino-Americans (reference group) Caucasians
RR 95% CI RR 95% CI RR 95% CI
Bivariate analysis 1.46 1.23 - 1.74 1.00 --- 1.53 1.32 - 1.77
After controlling for other variables
Age 1.82 1.53 - 2.16 1.00 --- 1.17 1.01 - 1.36
FIGO Stage 1.77 1.48 - 2.13 1.00 --- 1.19 1.02 - 1.39
Morphology 1.66 1.38 - 2.01 1.00 --- 1.49 1.27 - 1.75
Surgery 1.44 1.21 - 1.71 1.00 --- 1.41 1.22 - 1.64
Radiotherapy 1.60 1.34 - 1.91 1.00 --- 1.55 1.34 - 1.80
Multivariate analysis1 2.45 1.99 - 3.01 1.00 --- 1.17 0.99 - 1.37
RR, Relative Risk; 95% CI, 95% Confidence interval
1Controlling for all variables listed in the tableBMC Cancer 2009, 9:340 http://www.biomedcentral.com/1471-2407/9/340
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discontinue any form of therapy when it becomes an
excessive burden.
While much of the differences are likely to be explained by
health care access, dissimilar distributions by age, stage
and histology suggest a possible role of biological factors.
The differences in tumor biology between populations
might be reflective of the heterogeneous nature of ovarian
cancer, and should be investigated in more detail, given
that previous studies have shown significant variation of
survival by histologic subtypes [5,47-49].
Between Filipino-Americans and Caucasians, slightly
higher absolute and relative survival rates were observed
for the former group. The distributions by age and stage at
diagnosis vary between the groups, with Filipino-Ameri-
cans having more favorable characteristics. The Cox
model showed that the higher proportion of Caucasian
women with older age and advanced disease explains
most of the apparent survival difference. After adjustment
for these variables, as well as morphology and treatment,
the residual excess risk was small (15%) and not signifi-
cant. Sensitivity analyses regarding difference in survival
estimates between Caucasian population with and with-
out Hispanics did not show a significant difference.
Our study is limited to variables that were available and
comparable in the databases, and not all possible factors
that could affect survival were considered. Information on
chemotherapy is not included in the SEER public use data-
base whereas some tumor characteristics such as grade,
size and heterogeneity were not available from the Philip-
pine database. In addition, socio-economic status, family
history of ovarian cancer and lifestyle factors, like contra-
ceptive use and hormone intake, were also not studied.
Similarly, more detailed information on health care
access, particularly on access to and availability of various
treatment regimens, as well as application of treatment
guidelines, protocols used, specialization and expertise of
treating physicians, were not obtainable.
Patients with invalid data and those who do not have fol-
low-up time were excluded from the study, but it is
unlikely that they have higher survival than those who
were included. Most such patients have incomplete
records and were not traced to other hospitals in the NCR,
indicating that they might not have consulted physicians
after the initial diagnosis, or have had limited consulta-
tions afterwards. They most probably have not received
any form of treatment as the availability of cancer treat-
ment is limited outside the NCR. The survival rates pre-
sented might therefore overestimate true survival of
Philippine residents to some extent.
Conclusion
In conclusion, the results of the multivariate analyses dis-
closed strong survival disadvantages of Philippine resi-
dents compared to Filipino-American patients, despite
similar overall survival rates observed in the presence of
more favorable distributions of major prognostic factors.
The survival disadvantage of Philippine resident patients
most likely reflects differences in access to and affordabil-
ity of effective health care and treatment, such as chemo-
therapy. Emphasis should therefore be given on
improving access to and affordability of effective treat-
ment regimens. Prognosis is no worse among Filipino-
Americans than among Caucasians living in the US.
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